| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colitis, Ulcerative | 162 | 2024 | 736 | 38.090 |
Why?
|
| Inflammatory Bowel Diseases | 126 | 2024 | 575 | 29.550 |
Why?
|
| Crohn Disease | 125 | 2024 | 758 | 27.440 |
Why?
|
| Gastrointestinal Agents | 32 | 2024 | 171 | 8.730 |
Why?
|
| Antibodies, Monoclonal, Humanized | 40 | 2024 | 967 | 7.920 |
Why?
|
| Anti-Inflammatory Agents | 27 | 2021 | 345 | 6.850 |
Why?
|
| Colonoscopy | 44 | 2024 | 279 | 6.740 |
Why?
|
| Gastroenterology | 23 | 2023 | 144 | 6.530 |
Why?
|
| Colonic Pouches | 17 | 2023 | 68 | 6.120 |
Why?
|
| Colorectal Neoplasms | 36 | 2024 | 981 | 5.890 |
Why?
|
| Proctocolectomy, Restorative | 15 | 2023 | 88 | 5.470 |
Why?
|
| Adalimumab | 20 | 2024 | 86 | 5.430 |
Why?
|
| Remission Induction | 47 | 2024 | 740 | 4.900 |
Why?
|
| Humans | 411 | 2024 | 89073 | 4.890 |
Why?
|
| Colitis | 12 | 2022 | 244 | 4.820 |
Why?
|
| Infliximab | 18 | 2024 | 159 | 4.360 |
Why?
|
| Immunosuppressive Agents | 24 | 2023 | 975 | 4.180 |
Why?
|
| Biological Products | 15 | 2024 | 153 | 4.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 24 | 2021 | 699 | 4.020 |
Why?
|
| Mesalamine | 17 | 2024 | 88 | 3.880 |
Why?
|
| Colectomy | 17 | 2024 | 172 | 3.860 |
Why?
|
| Severity of Illness Index | 42 | 2024 | 1837 | 3.850 |
Why?
|
| Adult | 177 | 2024 | 26508 | 3.840 |
Why?
|
| Feces | 19 | 2023 | 327 | 3.570 |
Why?
|
| Piperidines | 13 | 2023 | 164 | 3.550 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 14 | 2021 | 242 | 3.540 |
Why?
|
| Ustekinumab | 9 | 2024 | 51 | 3.390 |
Why?
|
| Retrospective Studies | 85 | 2024 | 9003 | 3.380 |
Why?
|
| Pneumonia, Viral | 11 | 2020 | 319 | 3.240 |
Why?
|
| Coronavirus Infections | 11 | 2020 | 304 | 3.230 |
Why?
|
| Male | 189 | 2024 | 42254 | 3.220 |
Why?
|
| Middle Aged | 147 | 2024 | 25865 | 3.150 |
Why?
|
| Female | 195 | 2024 | 46014 | 3.030 |
Why?
|
| Disease Management | 13 | 2023 | 329 | 3.020 |
Why?
|
| Pyrimidines | 12 | 2023 | 372 | 3.010 |
Why?
|
| Endoscopy, Gastrointestinal | 12 | 2024 | 157 | 2.960 |
Why?
|
| Intestinal Mucosa | 25 | 2024 | 805 | 2.950 |
Why?
|
| Young Adult | 73 | 2024 | 6289 | 2.780 |
Why?
|
| Treatment Outcome | 71 | 2024 | 8203 | 2.710 |
Why?
|
| Indans | 6 | 2024 | 35 | 2.690 |
Why?
|
| Pouchitis | 9 | 2023 | 44 | 2.570 |
Why?
|
| Pyrroles | 10 | 2023 | 187 | 2.510 |
Why?
|
| Hospitalization | 16 | 2024 | 876 | 2.330 |
Why?
|
| Pandemics | 13 | 2021 | 771 | 2.310 |
Why?
|
| Clostridium Infections | 10 | 2023 | 124 | 2.230 |
Why?
|
| Colonic Neoplasms | 13 | 2019 | 573 | 2.210 |
Why?
|
| Practice Guidelines as Topic | 14 | 2020 | 1043 | 2.210 |
Why?
|
| Antibodies, Monoclonal | 16 | 2024 | 1401 | 2.160 |
Why?
|
| Azathioprine | 7 | 2021 | 124 | 2.100 |
Why?
|
| Quality of Life | 28 | 2024 | 1662 | 2.050 |
Why?
|
| Drug Monitoring | 8 | 2022 | 119 | 2.050 |
Why?
|
| Ileum | 12 | 2022 | 160 | 2.030 |
Why?
|
| Inflammation | 19 | 2023 | 971 | 2.030 |
Why?
|
| Oxadiazoles | 6 | 2024 | 38 | 2.000 |
Why?
|
| Betacoronavirus | 10 | 2020 | 261 | 1.970 |
Why?
|
| Precancerous Conditions | 10 | 2016 | 200 | 1.960 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 6 | 2024 | 31 | 1.930 |
Why?
|
| Physician-Patient Relations | 12 | 2021 | 625 | 1.920 |
Why?
|
| Tertiary Care Centers | 5 | 2024 | 106 | 1.850 |
Why?
|
| Biopsy | 12 | 2024 | 1182 | 1.820 |
Why?
|
| Gastroenterologists | 7 | 2023 | 31 | 1.820 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2021 | 604 | 1.760 |
Why?
|
| Maintenance Chemotherapy | 12 | 2021 | 84 | 1.680 |
Why?
|
| Induction Chemotherapy | 8 | 2022 | 151 | 1.680 |
Why?
|
| Leukocyte L1 Antigen Complex | 11 | 2024 | 45 | 1.670 |
Why?
|
| Colon | 17 | 2021 | 509 | 1.660 |
Why?
|
| Wound Healing | 9 | 2024 | 359 | 1.660 |
Why?
|
| Cholangitis, Sclerosing | 5 | 2023 | 51 | 1.640 |
Why?
|
| Diarrhea | 4 | 2020 | 182 | 1.560 |
Why?
|
| Adolescent | 48 | 2024 | 9237 | 1.550 |
Why?
|
| Microbiota | 11 | 2023 | 398 | 1.530 |
Why?
|
| Biological Therapy | 6 | 2022 | 47 | 1.490 |
Why?
|
| United States | 44 | 2024 | 6957 | 1.480 |
Why?
|
| Aged | 68 | 2024 | 19078 | 1.470 |
Why?
|
| Risk Factors | 42 | 2024 | 5466 | 1.440 |
Why?
|
| Immunologic Factors | 6 | 2023 | 171 | 1.430 |
Why?
|
| Cyclosporine | 6 | 2022 | 237 | 1.410 |
Why?
|
| Endoscopy | 14 | 2023 | 348 | 1.390 |
Why?
|
| Budesonide | 4 | 2019 | 46 | 1.380 |
Why?
|
| Clinical Trials as Topic | 10 | 2023 | 1149 | 1.380 |
Why?
|
| Transplantation | 3 | 2014 | 38 | 1.360 |
Why?
|
| Resuscitation Orders | 3 | 2021 | 63 | 1.350 |
Why?
|
| Calcineurin Inhibitors | 3 | 2021 | 53 | 1.330 |
Why?
|
| Anti-Bacterial Agents | 8 | 2021 | 786 | 1.320 |
Why?
|
| Fecal Microbiota Transplantation | 8 | 2023 | 64 | 1.320 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2022 | 169 | 1.320 |
Why?
|
| Janus Kinase Inhibitors | 5 | 2024 | 22 | 1.280 |
Why?
|
| Adenocarcinoma | 7 | 2019 | 1194 | 1.280 |
Why?
|
| Adrenal Cortex Hormones | 6 | 2024 | 266 | 1.270 |
Why?
|
| Prospective Studies | 25 | 2024 | 4273 | 1.260 |
Why?
|
| Research Subjects | 2 | 2021 | 73 | 1.260 |
Why?
|
| Secondary Prevention | 5 | 2021 | 158 | 1.240 |
Why?
|
| Mercaptopurine | 4 | 2018 | 53 | 1.240 |
Why?
|
| Intestinal Obstruction | 5 | 2016 | 88 | 1.220 |
Why?
|
| Symptom Flare Up | 3 | 2024 | 12 | 1.220 |
Why?
|
| Drug Therapy, Combination | 9 | 2021 | 783 | 1.210 |
Why?
|
| Follow-Up Studies | 25 | 2023 | 3657 | 1.190 |
Why?
|
| Glucocorticoids | 6 | 2020 | 357 | 1.190 |
Why?
|
| Recurrence | 18 | 2023 | 1140 | 1.160 |
Why?
|
| Infection Control | 4 | 2020 | 120 | 1.150 |
Why?
|
| Colonic Polyps | 9 | 2018 | 132 | 1.120 |
Why?
|
| Psoriasis | 2 | 2022 | 245 | 1.110 |
Why?
|
| Measles | 2 | 2016 | 16 | 1.100 |
Why?
|
| Postoperative Complications | 10 | 2022 | 2275 | 1.080 |
Why?
|
| Capsule Endoscopy | 6 | 2020 | 33 | 1.080 |
Why?
|
| Methotrexate | 2 | 2018 | 250 | 1.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 5 | 2022 | 203 | 1.080 |
Why?
|
| Digestive System Surgical Procedures | 6 | 2021 | 126 | 1.070 |
Why?
|
| Fellowships and Scholarships | 2 | 2019 | 121 | 1.060 |
Why?
|
| Case-Control Studies | 14 | 2024 | 1855 | 1.050 |
Why?
|
| Guanine Nucleotides | 2 | 2018 | 14 | 1.040 |
Why?
|
| Communication | 5 | 2024 | 457 | 1.040 |
Why?
|
| Intestine, Small | 6 | 2020 | 299 | 1.040 |
Why?
|
| Health Services Accessibility | 3 | 2021 | 424 | 1.030 |
Why?
|
| Thionucleotides | 2 | 2018 | 56 | 1.020 |
Why?
|
| Social Media | 2 | 2024 | 93 | 1.010 |
Why?
|
| Chronic Disease | 13 | 2023 | 948 | 1.000 |
Why?
|
| Prognosis | 27 | 2023 | 3773 | 0.990 |
Why?
|
| Patient Satisfaction | 4 | 2021 | 461 | 0.970 |
Why?
|
| Steroids | 4 | 2022 | 174 | 0.970 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2020 | 142 | 0.960 |
Why?
|
| Organometallic Compounds | 2 | 2020 | 134 | 0.940 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2017 | 237 | 0.930 |
Why?
|
| Biosensing Techniques | 2 | 2024 | 73 | 0.930 |
Why?
|
| Quality of Health Care | 4 | 2021 | 385 | 0.930 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2024 | 833 | 0.920 |
Why?
|
| Disease Progression | 19 | 2023 | 1488 | 0.920 |
Why?
|
| Double-Blind Method | 21 | 2024 | 1715 | 0.910 |
Why?
|
| C-Reactive Protein | 9 | 2023 | 192 | 0.910 |
Why?
|
| Symptom Assessment | 2 | 2021 | 66 | 0.900 |
Why?
|
| Rectum | 5 | 2023 | 148 | 0.900 |
Why?
|
| Patient Selection | 3 | 2024 | 682 | 0.900 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2024 | 27 | 0.880 |
Why?
|
| Biomarkers | 15 | 2024 | 1755 | 0.870 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2020 | 46 | 0.870 |
Why?
|
| Time Factors | 19 | 2024 | 5320 | 0.850 |
Why?
|
| Health Personnel | 2 | 2024 | 212 | 0.850 |
Why?
|
| Proctitis | 4 | 2022 | 12 | 0.840 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2021 | 257 | 0.840 |
Why?
|
| Aged, 80 and over | 24 | 2023 | 6777 | 0.840 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2022 | 11 | 0.830 |
Why?
|
| Ileal Neoplasms | 1 | 2022 | 9 | 0.830 |
Why?
|
| Colonography, Computed Tomographic | 6 | 2010 | 81 | 0.810 |
Why?
|
| Health Care Costs | 6 | 2021 | 235 | 0.800 |
Why?
|
| Incidence | 17 | 2023 | 1592 | 0.800 |
Why?
|
| Physicians | 4 | 2021 | 689 | 0.790 |
Why?
|
| Clinical Competence | 2 | 2019 | 780 | 0.790 |
Why?
|
| Insurance, Health | 2 | 2020 | 159 | 0.780 |
Why?
|
| Intestinal Neoplasms | 1 | 2022 | 64 | 0.780 |
Why?
|
| Arthritis, Psoriatic | 2 | 2022 | 34 | 0.760 |
Why?
|
| Predictive Value of Tests | 9 | 2024 | 1715 | 0.760 |
Why?
|
| Sleep Wake Disorders | 2 | 2020 | 117 | 0.760 |
Why?
|
| Tertiary Healthcare | 1 | 2020 | 5 | 0.750 |
Why?
|
| Multiple Chronic Conditions | 1 | 2020 | 5 | 0.750 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 26 | 0.740 |
Why?
|
| Case Management | 1 | 2020 | 25 | 0.740 |
Why?
|
| Cohort Studies | 15 | 2024 | 2863 | 0.740 |
Why?
|
| Smoking | 5 | 2020 | 620 | 0.740 |
Why?
|
| Bismuth | 1 | 2020 | 8 | 0.740 |
Why?
|
| Basic Reproduction Number | 1 | 2020 | 6 | 0.730 |
Why?
|
| Antidiarrheals | 1 | 2020 | 14 | 0.730 |
Why?
|
| Patellar Dislocation | 1 | 2020 | 12 | 0.730 |
Why?
|
| Salicylates | 1 | 2020 | 25 | 0.720 |
Why?
|
| Anastomosis, Surgical | 8 | 2022 | 273 | 0.720 |
Why?
|
| Intestinal Fistula | 3 | 2021 | 31 | 0.720 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2020 | 20 | 0.710 |
Why?
|
| Vancomycin | 2 | 2020 | 73 | 0.710 |
Why?
|
| Cough | 1 | 2020 | 55 | 0.710 |
Why?
|
| Lymph Nodes | 1 | 2024 | 548 | 0.710 |
Why?
|
| Population Density | 1 | 2020 | 61 | 0.710 |
Why?
|
| Health Care Rationing | 1 | 2020 | 83 | 0.710 |
Why?
|
| Mucous Membrane | 3 | 2023 | 83 | 0.700 |
Why?
|
| Surveys and Questionnaires | 15 | 2024 | 2612 | 0.700 |
Why?
|
| Attitude to Health | 4 | 2017 | 222 | 0.700 |
Why?
|
| Metronidazole | 1 | 2019 | 26 | 0.690 |
Why?
|
| Drug Resistance | 2 | 2019 | 232 | 0.690 |
Why?
|
| History, 20th Century | 7 | 2014 | 310 | 0.680 |
Why?
|
| Drug Administration Schedule | 7 | 2019 | 894 | 0.680 |
Why?
|
| Joint Instability | 1 | 2020 | 82 | 0.680 |
Why?
|
| Perception | 3 | 2024 | 178 | 0.670 |
Why?
|
| Knee Joint | 1 | 2020 | 165 | 0.670 |
Why?
|
| Polyethylene Glycols | 4 | 2018 | 358 | 0.660 |
Why?
|
| Medical Marijuana | 1 | 2019 | 7 | 0.660 |
Why?
|
| Gastrointestinal Tract | 3 | 2017 | 191 | 0.660 |
Why?
|
| Temperature | 1 | 2020 | 400 | 0.650 |
Why?
|
| Government Regulation | 1 | 2019 | 49 | 0.650 |
Why?
|
| Radiography, Abdominal | 1 | 2019 | 69 | 0.650 |
Why?
|
| Genetic Testing | 3 | 2009 | 537 | 0.640 |
Why?
|
| Renal Nutcracker Syndrome | 1 | 2018 | 2 | 0.630 |
Why?
|
| Nephrotic Syndrome | 1 | 2018 | 33 | 0.620 |
Why?
|
| Intestines | 7 | 2024 | 416 | 0.620 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2021 | 599 | 0.620 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2024 | 1940 | 0.620 |
Why?
|
| Curriculum | 2 | 2021 | 567 | 0.620 |
Why?
|
| Risk Assessment | 15 | 2021 | 2291 | 0.610 |
Why?
|
| Hematuria | 1 | 2018 | 50 | 0.610 |
Why?
|
| Spondylitis, Ankylosing | 2 | 2017 | 25 | 0.610 |
Why?
|
| Drug Approval | 1 | 2018 | 66 | 0.610 |
Why?
|
| Mental Recall | 2 | 2011 | 157 | 0.600 |
Why?
|
| Antibodies, Viral | 2 | 2016 | 309 | 0.600 |
Why?
|
| Quality Improvement | 2 | 2021 | 447 | 0.590 |
Why?
|
| Colonoscopes | 2 | 2015 | 13 | 0.590 |
Why?
|
| Digestive System Diseases | 1 | 2017 | 18 | 0.580 |
Why?
|
| Proportional Hazards Models | 6 | 2024 | 848 | 0.580 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2017 | 73 | 0.570 |
Why?
|
| Celiac Disease | 1 | 2020 | 213 | 0.570 |
Why?
|
| Early Detection of Cancer | 3 | 2019 | 415 | 0.570 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 244 | 0.570 |
Why?
|
| Ostomy | 2 | 2020 | 15 | 0.560 |
Why?
|
| Proctocolitis | 2 | 2016 | 3 | 0.560 |
Why?
|
| Morbillivirus | 1 | 2016 | 2 | 0.560 |
Why?
|
| Whooping Cough | 1 | 2016 | 3 | 0.560 |
Why?
|
| Histiocytosis, Sinus | 1 | 2016 | 15 | 0.560 |
Why?
|
| Bordetella pertussis | 1 | 2016 | 15 | 0.560 |
Why?
|
| Global Health | 3 | 2024 | 186 | 0.550 |
Why?
|
| Zinc | 1 | 2017 | 93 | 0.550 |
Why?
|
| Mass Screening | 7 | 2020 | 636 | 0.540 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2016 | 7 | 0.540 |
Why?
|
| Deception | 1 | 2016 | 20 | 0.540 |
Why?
|
| Positron-Emission Tomography | 3 | 2020 | 336 | 0.540 |
Why?
|
| Patient Dropouts | 1 | 2016 | 30 | 0.540 |
Why?
|
| Antibodies, Bacterial | 1 | 2016 | 99 | 0.540 |
Why?
|
| Liver Diseases | 1 | 2018 | 242 | 0.530 |
Why?
|
| Cost of Illness | 5 | 2020 | 147 | 0.530 |
Why?
|
| Antibodies | 2 | 2017 | 353 | 0.520 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 93 | 0.520 |
Why?
|
| Immunoglobulin Fab Fragments | 3 | 2014 | 83 | 0.520 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 390 | 0.510 |
Why?
|
| Mesentery | 1 | 2015 | 45 | 0.510 |
Why?
|
| History, 21st Century | 5 | 2014 | 180 | 0.500 |
Why?
|
| Diverticulum | 1 | 2015 | 45 | 0.500 |
Why?
|
| Europe | 4 | 2024 | 321 | 0.500 |
Why?
|
| Allopurinol | 2 | 2013 | 77 | 0.500 |
Why?
|
| Liver | 2 | 2018 | 1205 | 0.500 |
Why?
|
| Problem-Based Learning | 1 | 2015 | 32 | 0.500 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2020 | 3443 | 0.490 |
Why?
|
| Antirheumatic Agents | 3 | 2021 | 55 | 0.490 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2014 | 24 | 0.480 |
Why?
|
| Ambulatory Care | 3 | 2021 | 187 | 0.480 |
Why?
|
| Cholagogues and Choleretics | 1 | 2014 | 10 | 0.480 |
Why?
|
| Neoplasms, Second Primary | 4 | 2012 | 260 | 0.480 |
Why?
|
| Adenomatous Polyposis Coli | 3 | 2022 | 39 | 0.470 |
Why?
|
| Carcinoma | 2 | 2014 | 443 | 0.470 |
Why?
|
| Child | 15 | 2022 | 7149 | 0.470 |
Why?
|
| Ileitis | 1 | 2014 | 7 | 0.470 |
Why?
|
| Ultrasonography | 4 | 2024 | 711 | 0.470 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 207 | 0.470 |
Why?
|
| Administration, Oral | 6 | 2021 | 682 | 0.460 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2020 | 248 | 0.460 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2013 | 31 | 0.450 |
Why?
|
| Drug Prescriptions | 3 | 2020 | 144 | 0.440 |
Why?
|
| Societies, Medical | 4 | 2021 | 570 | 0.440 |
Why?
|
| Gastric Mucosa | 1 | 2013 | 66 | 0.440 |
Why?
|
| Neuroendocrine Tumors | 1 | 2015 | 117 | 0.440 |
Why?
|
| Biomedical Research | 3 | 2024 | 398 | 0.430 |
Why?
|
| Enteritis | 1 | 2013 | 21 | 0.430 |
Why?
|
| Metagenome | 1 | 2013 | 104 | 0.420 |
Why?
|
| Gastritis | 1 | 2013 | 36 | 0.420 |
Why?
|
| Referral and Consultation | 3 | 2023 | 341 | 0.420 |
Why?
|
| Opportunistic Infections | 2 | 2023 | 60 | 0.420 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2012 | 52 | 0.410 |
Why?
|
| Drug Substitution | 2 | 2024 | 26 | 0.410 |
Why?
|
| Contrast Media | 5 | 2019 | 1090 | 0.410 |
Why?
|
| Hyperplasia | 2 | 2022 | 152 | 0.400 |
Why?
|
| Periodicals as Topic | 1 | 2014 | 168 | 0.390 |
Why?
|
| Logistic Models | 7 | 2018 | 1212 | 0.390 |
Why?
|
| Abdominal Pain | 6 | 2023 | 138 | 0.390 |
Why?
|
| Hematologic Diseases | 1 | 2011 | 78 | 0.380 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2009 | 109 | 0.380 |
Why?
|
| Evidence-Based Practice | 1 | 2011 | 47 | 0.380 |
Why?
|
| Malnutrition | 1 | 2011 | 32 | 0.380 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2010 | 447 | 0.380 |
Why?
|
| Population Surveillance | 7 | 2016 | 216 | 0.380 |
Why?
|
| Attitude | 1 | 2012 | 130 | 0.380 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2014 | 260 | 0.380 |
Why?
|
| Medication Adherence | 4 | 2019 | 138 | 0.370 |
Why?
|
| Length of Stay | 3 | 2021 | 732 | 0.370 |
Why?
|
| Rectal Neoplasms | 2 | 2009 | 127 | 0.360 |
Why?
|
| Chicago | 8 | 2018 | 1423 | 0.360 |
Why?
|
| Appendix | 1 | 2010 | 31 | 0.360 |
Why?
|
| Smoking Cessation | 2 | 2012 | 252 | 0.360 |
Why?
|
| Sulfasalazine | 2 | 2007 | 34 | 0.360 |
Why?
|
| Longitudinal Studies | 6 | 2020 | 1067 | 0.350 |
Why?
|
| Natalizumab | 3 | 2015 | 21 | 0.350 |
Why?
|
| Family | 2 | 2009 | 325 | 0.350 |
Why?
|
| Odds Ratio | 4 | 2021 | 684 | 0.350 |
Why?
|
| Sick Role | 1 | 2009 | 13 | 0.350 |
Why?
|
| Aminosalicylic Acids | 2 | 2006 | 41 | 0.340 |
Why?
|
| Prefrontal Cortex | 1 | 2011 | 134 | 0.340 |
Why?
|
| Pharmacogenetics | 3 | 2019 | 443 | 0.340 |
Why?
|
| Anastomotic Leak | 3 | 2021 | 103 | 0.340 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2013 | 531 | 0.340 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 1706 | 0.340 |
Why?
|
| Biosimilar Pharmaceuticals | 2 | 2020 | 23 | 0.340 |
Why?
|
| Radiotherapy | 3 | 2012 | 331 | 0.330 |
Why?
|
| Reproducibility of Results | 10 | 2023 | 2752 | 0.330 |
Why?
|
| Consensus | 8 | 2023 | 356 | 0.330 |
Why?
|
| Sarcoma, Myeloid | 1 | 2009 | 15 | 0.330 |
Why?
|
| Memory | 1 | 2011 | 220 | 0.330 |
Why?
|
| Mandibular Neoplasms | 1 | 2009 | 23 | 0.330 |
Why?
|
| Colonic Diseases | 2 | 2021 | 61 | 0.330 |
Why?
|
| Infusions, Intravenous | 3 | 2024 | 434 | 0.330 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 2020 | 60 | 0.330 |
Why?
|
| Focus Groups | 1 | 2009 | 170 | 0.320 |
Why?
|
| Immunocompromised Host | 3 | 2020 | 142 | 0.320 |
Why?
|
| Intestine, Large | 1 | 2008 | 15 | 0.320 |
Why?
|
| Medical Records | 2 | 2017 | 120 | 0.310 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2011 | 302 | 0.310 |
Why?
|
| Corynebacterium Infections | 1 | 2008 | 3 | 0.310 |
Why?
|
| Corynebacterium | 1 | 2008 | 9 | 0.310 |
Why?
|
| Patients | 1 | 2009 | 102 | 0.310 |
Why?
|
| Databases, Factual | 5 | 2019 | 850 | 0.310 |
Why?
|
| Precision Medicine | 3 | 2024 | 410 | 0.310 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 193 | 0.300 |
Why?
|
| Certolizumab Pegol | 4 | 2016 | 19 | 0.300 |
Why?
|
| Professional Practice | 1 | 2008 | 46 | 0.300 |
Why?
|
| Reinforcement, Verbal | 1 | 2007 | 5 | 0.300 |
Why?
|
| Brain Mapping | 1 | 2011 | 564 | 0.300 |
Why?
|
| Vitamin D Deficiency | 2 | 2021 | 103 | 0.300 |
Why?
|
| Cytomegalovirus Infections | 2 | 2022 | 146 | 0.300 |
Why?
|
| Mammaplasty | 2 | 2020 | 109 | 0.290 |
Why?
|
| Professional Competence | 1 | 2008 | 69 | 0.290 |
Why?
|
| Leukemic Infiltration | 1 | 2007 | 14 | 0.290 |
Why?
|
| Histocytochemistry | 3 | 2017 | 130 | 0.290 |
Why?
|
| Aspirin | 2 | 2021 | 159 | 0.290 |
Why?
|
| Registries | 4 | 2020 | 778 | 0.290 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 988 | 0.290 |
Why?
|
| Urologic Neoplasms | 1 | 2008 | 82 | 0.290 |
Why?
|
| Genes, p53 | 1 | 2007 | 109 | 0.290 |
Why?
|
| Health Expenditures | 2 | 2020 | 91 | 0.290 |
Why?
|
| Sensitivity and Specificity | 11 | 2018 | 2014 | 0.290 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2007 | 21 | 0.290 |
Why?
|
| Placebos | 3 | 2024 | 214 | 0.280 |
Why?
|
| Insurance Claim Review | 3 | 2018 | 45 | 0.280 |
Why?
|
| Adenoma | 3 | 2015 | 246 | 0.280 |
Why?
|
| Interprofessional Relations | 2 | 2008 | 122 | 0.280 |
Why?
|
| Gastrointestinal Microbiome | 4 | 2023 | 504 | 0.280 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 859 | 0.280 |
Why?
|
| Patient Acuity | 3 | 2021 | 33 | 0.280 |
Why?
|
| Cathartics | 1 | 2006 | 27 | 0.280 |
Why?
|
| Citric Acid | 1 | 2006 | 38 | 0.280 |
Why?
|
| Disclosure | 1 | 2007 | 110 | 0.270 |
Why?
|
| Dietary Fiber | 1 | 2006 | 44 | 0.270 |
Why?
|
| MicroRNAs | 3 | 2017 | 551 | 0.270 |
Why?
|
| Genetic Counseling | 1 | 2006 | 101 | 0.270 |
Why?
|
| Clinical Laboratory Techniques | 3 | 2020 | 76 | 0.270 |
Why?
|
| Prevalence | 8 | 2021 | 1240 | 0.270 |
Why?
|
| International Cooperation | 3 | 2021 | 125 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2017 | 1265 | 0.260 |
Why?
|
| Phenotype | 3 | 2022 | 2439 | 0.260 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2009 | 2335 | 0.260 |
Why?
|
| Diagnosis, Differential | 6 | 2016 | 1591 | 0.260 |
Why?
|
| Ileal Diseases | 3 | 2019 | 26 | 0.250 |
Why?
|
| Mesenteric Veins | 1 | 2005 | 33 | 0.250 |
Why?
|
| Propensity Score | 3 | 2021 | 147 | 0.250 |
Why?
|
| Constriction, Pathologic | 4 | 2021 | 217 | 0.250 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2024 | 7 | 0.250 |
Why?
|
| Holistic Health | 1 | 2024 | 9 | 0.240 |
Why?
|
| Algorithms | 5 | 2011 | 1875 | 0.240 |
Why?
|
| Age Factors | 7 | 2021 | 1867 | 0.240 |
Why?
|
| Delayed-Action Preparations | 2 | 2017 | 110 | 0.240 |
Why?
|
| Laparoscopy | 1 | 2011 | 771 | 0.240 |
Why?
|
| Luminescent Measurements | 1 | 2024 | 62 | 0.230 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 160 | 0.230 |
Why?
|
| Pregnancy Complications | 2 | 2020 | 345 | 0.230 |
Why?
|
| Sepsis | 1 | 2008 | 319 | 0.230 |
Why?
|
| Endpoint Determination | 2 | 2021 | 61 | 0.230 |
Why?
|
| Documentation | 3 | 2023 | 103 | 0.230 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 49 | 0.230 |
Why?
|
| Venous Thrombosis | 2 | 2011 | 250 | 0.220 |
Why?
|
| Blood Sedimentation | 2 | 2020 | 13 | 0.220 |
Why?
|
| Health Services | 2 | 2021 | 57 | 0.220 |
Why?
|
| Metagenomics | 3 | 2023 | 88 | 0.220 |
Why?
|
| Nervous System Diseases | 1 | 2024 | 162 | 0.220 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2021 | 172 | 0.220 |
Why?
|
| Research Design | 3 | 2023 | 597 | 0.220 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 112 | 0.220 |
Why?
|
| Statistics, Nonparametric | 2 | 2017 | 306 | 0.220 |
Why?
|
| Ulcer | 2 | 2022 | 37 | 0.220 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2005 | 387 | 0.210 |
Why?
|
| Inpatients | 3 | 2021 | 310 | 0.210 |
Why?
|
| Patient Care Team | 2 | 2020 | 283 | 0.210 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 385 | 0.210 |
Why?
|
| Child, Preschool | 5 | 2020 | 3717 | 0.210 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 1796 | 0.210 |
Why?
|
| Cost-Benefit Analysis | 3 | 2021 | 461 | 0.210 |
Why?
|
| Enterocolitis | 1 | 2022 | 13 | 0.210 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2009 | 788 | 0.210 |
Why?
|
| Ileostomy | 2 | 2019 | 29 | 0.200 |
Why?
|
| Health Care Surveys | 3 | 2021 | 280 | 0.200 |
Why?
|
| Treatment Failure | 2 | 2019 | 287 | 0.200 |
Why?
|
| Breast Implants | 2 | 2020 | 25 | 0.200 |
Why?
|
| Compliance | 1 | 2021 | 21 | 0.200 |
Why?
|
| Interleukin-23 | 1 | 2022 | 57 | 0.200 |
Why?
|
| Committee Membership | 1 | 2021 | 4 | 0.200 |
Why?
|
| Clinical Decision-Making | 3 | 2021 | 280 | 0.200 |
Why?
|
| Interleukin-12 | 1 | 2022 | 109 | 0.200 |
Why?
|
| Internationality | 1 | 2021 | 69 | 0.200 |
Why?
|
| Marketing | 1 | 2021 | 23 | 0.200 |
Why?
|
| Control Groups | 1 | 2021 | 15 | 0.190 |
Why?
|
| Bibliometrics | 1 | 2021 | 37 | 0.190 |
Why?
|
| Career Mobility | 1 | 2021 | 31 | 0.190 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 10 | 0.190 |
Why?
|
| Free Tissue Flaps | 2 | 2020 | 49 | 0.190 |
Why?
|
| Azithromycin | 1 | 2021 | 13 | 0.190 |
Why?
|
| North America | 1 | 2021 | 184 | 0.190 |
Why?
|
| Guidelines as Topic | 2 | 2021 | 160 | 0.190 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2012 | 111 | 0.190 |
Why?
|
| Th17 Cells | 2 | 2019 | 84 | 0.190 |
Why?
|
| Societies, Scientific | 1 | 2021 | 43 | 0.190 |
Why?
|
| Congresses as Topic | 2 | 2020 | 112 | 0.190 |
Why?
|
| Acute Disease | 2 | 2021 | 841 | 0.190 |
Why?
|
| Arthralgia | 2 | 2019 | 39 | 0.190 |
Why?
|
| Deprescriptions | 1 | 2021 | 6 | 0.190 |
Why?
|
| Long QT Syndrome | 1 | 2021 | 36 | 0.190 |
Why?
|
| Pressure | 1 | 2021 | 165 | 0.190 |
Why?
|
| Self Report | 1 | 2022 | 295 | 0.190 |
Why?
|
| Hospital Restructuring | 1 | 2020 | 3 | 0.190 |
Why?
|
| Ethics, Medical | 2 | 2021 | 307 | 0.190 |
Why?
|
| Intention to Treat Analysis | 2 | 2018 | 69 | 0.190 |
Why?
|
| Cardiac Electrophysiology | 1 | 2020 | 7 | 0.190 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 172 | 0.180 |
Why?
|
| Decision Trees | 1 | 2020 | 59 | 0.180 |
Why?
|
| Bacteria | 3 | 2023 | 472 | 0.180 |
Why?
|
| Information Dissemination | 1 | 2021 | 114 | 0.180 |
Why?
|
| Markov Chains | 1 | 2021 | 127 | 0.180 |
Why?
|
| Lymphopenia | 1 | 2020 | 31 | 0.180 |
Why?
|
| Infant | 5 | 2020 | 3147 | 0.180 |
Why?
|
| Survivors | 2 | 2012 | 233 | 0.180 |
Why?
|
| Patient Care Management | 1 | 2020 | 30 | 0.180 |
Why?
|
| Evaluation Studies as Topic | 1 | 2020 | 270 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 322 | 0.180 |
Why?
|
| Methylprednisolone | 1 | 2020 | 64 | 0.180 |
Why?
|
| Epidemiological Monitoring | 1 | 2020 | 39 | 0.180 |
Why?
|
| Prostatic Neoplasms | 2 | 2009 | 1768 | 0.180 |
Why?
|
| Retreatment | 2 | 2017 | 108 | 0.180 |
Why?
|
| Endoscopy, Digestive System | 2 | 2018 | 68 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2020 | 2657 | 0.180 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2020 | 19 | 0.180 |
Why?
|
| Surgical Stomas | 1 | 2020 | 22 | 0.180 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2021 | 142 | 0.180 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 33 | 0.180 |
Why?
|
| Safety Management | 1 | 2020 | 56 | 0.180 |
Why?
|
| Drug Costs | 2 | 2019 | 63 | 0.180 |
Why?
|
| Carcinogenesis | 2 | 2019 | 211 | 0.180 |
Why?
|
| Pharmacogenomic Testing | 2 | 2019 | 98 | 0.170 |
Why?
|
| Triage | 1 | 2020 | 111 | 0.170 |
Why?
|
| Reoperation | 2 | 2020 | 598 | 0.170 |
Why?
|
| Point-of-Care Systems | 2 | 2019 | 148 | 0.170 |
Why?
|
| Universities | 1 | 2020 | 146 | 0.170 |
Why?
|
| Infant, Newborn | 4 | 2020 | 2476 | 0.170 |
Why?
|
| Abortion, Spontaneous | 1 | 2020 | 66 | 0.170 |
Why?
|
| User-Computer Interface | 1 | 2001 | 187 | 0.170 |
Why?
|
| Leadership | 1 | 2021 | 138 | 0.170 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 58 | 0.170 |
Why?
|
| Biomarkers, Tumor | 6 | 2018 | 1543 | 0.170 |
Why?
|
| Anxiety | 2 | 2021 | 308 | 0.170 |
Why?
|
| Renin-Angiotensin System | 2 | 2019 | 81 | 0.170 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 16 | 0.170 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2017 | 105 | 0.170 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 521 | 0.170 |
Why?
|
| Influenza Vaccines | 1 | 2020 | 148 | 0.170 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 214 | 0.170 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2019 | 15 | 0.170 |
Why?
|
| Microsurgery | 1 | 2020 | 88 | 0.170 |
Why?
|
| Electrophysiology | 1 | 2020 | 403 | 0.170 |
Why?
|
| Anemia | 1 | 2020 | 129 | 0.170 |
Why?
|
| Administration, Rectal | 2 | 2016 | 12 | 0.170 |
Why?
|
| Faculty, Medical | 1 | 2021 | 185 | 0.170 |
Why?
|
| Health Status Disparities | 1 | 2021 | 187 | 0.170 |
Why?
|
| Constipation | 1 | 2020 | 63 | 0.170 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 372 | 0.160 |
Why?
|
| Foreign Bodies | 1 | 2020 | 66 | 0.160 |
Why?
|
| European Union | 1 | 2018 | 8 | 0.160 |
Why?
|
| Caregivers | 1 | 2020 | 159 | 0.160 |
Why?
|
| Consent Forms | 1 | 2018 | 11 | 0.160 |
Why?
|
| Government Agencies | 1 | 2018 | 11 | 0.160 |
Why?
|
| Prescription Drugs | 1 | 2019 | 36 | 0.160 |
Why?
|
| Vaccination | 1 | 2021 | 273 | 0.160 |
Why?
|
| Arthritis | 1 | 2019 | 47 | 0.160 |
Why?
|
| Immune System Diseases | 1 | 2019 | 27 | 0.160 |
Why?
|
| Electrocardiography | 1 | 2021 | 493 | 0.160 |
Why?
|
| Thrombosis | 1 | 2021 | 302 | 0.160 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2018 | 19 | 0.160 |
Why?
|
| Health Resources | 1 | 2019 | 81 | 0.160 |
Why?
|
| Renal Veins | 1 | 2018 | 28 | 0.160 |
Why?
|
| Aberrant Crypt Foci | 1 | 2018 | 7 | 0.160 |
Why?
|
| Malpractice | 1 | 2018 | 57 | 0.160 |
Why?
|
| Health Policy | 1 | 2020 | 184 | 0.150 |
Why?
|
| Laxatives | 1 | 2018 | 13 | 0.150 |
Why?
|
| Vitamin D | 2 | 2021 | 268 | 0.150 |
Why?
|
| SEER Program | 2 | 2009 | 197 | 0.150 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2021 | 173 | 0.150 |
Why?
|
| Liver Function Tests | 1 | 2018 | 92 | 0.150 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 135 | 0.150 |
Why?
|
| Depression | 2 | 2021 | 503 | 0.150 |
Why?
|
| Anticarcinogenic Agents | 1 | 2018 | 73 | 0.150 |
Why?
|
| Thrombospondins | 1 | 2017 | 14 | 0.150 |
Why?
|
| Caveolin 1 | 1 | 2017 | 21 | 0.150 |
Why?
|
| Medical Errors | 1 | 2018 | 117 | 0.150 |
Why?
|
| Treatment Refusal | 2 | 2008 | 62 | 0.150 |
Why?
|
| Telemedicine | 1 | 2020 | 185 | 0.150 |
Why?
|
| Uncertainty | 2 | 2009 | 74 | 0.150 |
Why?
|
| Influenza, Human | 1 | 2020 | 337 | 0.150 |
Why?
|
| Receptors, Interleukin | 1 | 2017 | 36 | 0.150 |
Why?
|
| Syndrome | 1 | 2018 | 449 | 0.150 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 529 | 0.150 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 25 | 0.150 |
Why?
|
| Up-Regulation | 2 | 2018 | 727 | 0.150 |
Why?
|
| Collagen Type I | 1 | 2017 | 72 | 0.140 |
Why?
|
| Animals | 11 | 2020 | 27324 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 153 | 0.140 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 705 | 0.140 |
Why?
|
| Managed Care Programs | 1 | 2017 | 42 | 0.140 |
Why?
|
| Comorbidity | 4 | 2021 | 948 | 0.140 |
Why?
|
| Pertussis Vaccine | 1 | 2016 | 2 | 0.140 |
Why?
|
| Measles Vaccine | 1 | 2016 | 8 | 0.140 |
Why?
|
| Patient Education as Topic | 3 | 2009 | 359 | 0.140 |
Why?
|
| Focal Adhesions | 1 | 2017 | 70 | 0.140 |
Why?
|
| Tacrolimus | 1 | 2018 | 369 | 0.140 |
Why?
|
| Vena Cava, Inferior | 1 | 2018 | 145 | 0.140 |
Why?
|
| Mental Health | 1 | 2018 | 176 | 0.140 |
Why?
|
| Patient Compliance | 2 | 2008 | 230 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 410 | 0.140 |
Why?
|
| Immunization, Secondary | 1 | 2016 | 32 | 0.140 |
Why?
|
| Genetic Markers | 2 | 2014 | 478 | 0.140 |
Why?
|
| Bacteroides | 1 | 2016 | 34 | 0.140 |
Why?
|
| Chemoprevention | 3 | 2018 | 92 | 0.140 |
Why?
|
| Illinois | 3 | 2019 | 472 | 0.140 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 1429 | 0.140 |
Why?
|
| Renin | 1 | 2016 | 67 | 0.140 |
Why?
|
| Gastrointestinal Motility | 1 | 2016 | 25 | 0.140 |
Why?
|
| Image-Guided Biopsy | 1 | 2016 | 68 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 1363 | 0.130 |
Why?
|
| Risk | 2 | 2008 | 657 | 0.130 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 751 | 0.130 |
Why?
|
| Sleep | 1 | 2020 | 452 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2020 | 412 | 0.130 |
Why?
|
| Neoplasms | 4 | 2019 | 3035 | 0.130 |
Why?
|
| Dosage Forms | 1 | 2015 | 7 | 0.130 |
Why?
|
| Forecasting | 1 | 2017 | 305 | 0.130 |
Why?
|
| Barium Sulfate | 2 | 2006 | 43 | 0.130 |
Why?
|
| Integrins | 1 | 2016 | 78 | 0.130 |
Why?
|
| Health Status | 1 | 2018 | 370 | 0.130 |
Why?
|
| Ethics, Research | 1 | 2016 | 52 | 0.130 |
Why?
|
| Dehydration | 1 | 2015 | 20 | 0.130 |
Why?
|
| Intraabdominal Infections | 1 | 2015 | 10 | 0.130 |
Why?
|
| Genome, Bacterial | 1 | 2016 | 148 | 0.130 |
Why?
|
| Anus Diseases | 1 | 2015 | 15 | 0.130 |
Why?
|
| JC Virus | 1 | 2015 | 5 | 0.130 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2016 | 91 | 0.130 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2015 | 13 | 0.130 |
Why?
|
| Hydrocortisone | 1 | 2017 | 302 | 0.130 |
Why?
|
| Double-Balloon Enteroscopy | 1 | 2015 | 11 | 0.130 |
Why?
|
| Spectrum Analysis | 1 | 2015 | 119 | 0.130 |
Why?
|
| Physician's Role | 1 | 2017 | 177 | 0.130 |
Why?
|
| Interleukin-10 | 1 | 2016 | 151 | 0.130 |
Why?
|
| Life Style | 2 | 2022 | 172 | 0.130 |
Why?
|
| Communicable Diseases | 1 | 2016 | 63 | 0.130 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 201 | 0.130 |
Why?
|
| Dysbiosis | 1 | 2016 | 77 | 0.120 |
Why?
|
| Salvage Therapy | 2 | 2014 | 235 | 0.120 |
Why?
|
| Disability Evaluation | 2 | 2020 | 140 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 1176 | 0.120 |
Why?
|
| Cladribine | 1 | 2014 | 35 | 0.120 |
Why?
|
| ErbB Receptors | 1 | 2018 | 500 | 0.120 |
Why?
|
| Catheters | 1 | 2015 | 76 | 0.120 |
Why?
|
| Discriminant Analysis | 2 | 2013 | 67 | 0.120 |
Why?
|
| Intestinal Diseases | 1 | 2015 | 79 | 0.120 |
Why?
|
| Antigens, CD1 | 1 | 2014 | 37 | 0.120 |
Why?
|
| Coloring Agents | 1 | 2014 | 65 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2019 | 657 | 0.120 |
Why?
|
| Intestinal Polyps | 2 | 2021 | 27 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2020 | 669 | 0.120 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 236 | 0.120 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2014 | 25 | 0.120 |
Why?
|
| Epidemiologic Methods | 2 | 2011 | 60 | 0.120 |
Why?
|
| History, 18th Century | 1 | 2014 | 21 | 0.120 |
Why?
|
| Delphi Technique | 3 | 2021 | 92 | 0.120 |
Why?
|
| Integrin alpha4 | 1 | 2013 | 11 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 311 | 0.120 |
Why?
|
| Mentors | 1 | 2015 | 85 | 0.120 |
Why?
|
| History, 19th Century | 1 | 2014 | 56 | 0.110 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 146 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2017 | 351 | 0.110 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2013 | 21 | 0.110 |
Why?
|
| Subarachnoid Space | 1 | 2013 | 17 | 0.110 |
Why?
|
| Hematoma, Subdural | 1 | 2013 | 25 | 0.110 |
Why?
|
| Snoring | 1 | 2012 | 12 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2008 | 103 | 0.110 |
Why?
|
| Serum | 1 | 2012 | 25 | 0.110 |
Why?
|
| Transcriptome | 1 | 2017 | 628 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 268 | 0.100 |
Why?
|
| Antimetabolites | 1 | 2011 | 24 | 0.100 |
Why?
|
| Lymphogranuloma Venereum | 1 | 2011 | 1 | 0.100 |
Why?
|
| Data Collection | 3 | 2009 | 375 | 0.100 |
Why?
|
| Hand-Assisted Laparoscopy | 1 | 2011 | 1 | 0.100 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2012 | 107 | 0.100 |
Why?
|
| Gonorrhea | 1 | 2011 | 22 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 146 | 0.100 |
Why?
|
| Chlamydia Infections | 1 | 2011 | 30 | 0.100 |
Why?
|
| Virus Latency | 1 | 2011 | 33 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2021 | 1041 | 0.100 |
Why?
|
| Proto-Oncogenes | 1 | 2011 | 61 | 0.100 |
Why?
|
| Syphilis | 1 | 2011 | 33 | 0.090 |
Why?
|
| Nicotinic Agonists | 1 | 2012 | 73 | 0.090 |
Why?
|
| Diffusion | 1 | 2011 | 93 | 0.090 |
Why?
|
| Guideline Adherence | 1 | 2012 | 229 | 0.090 |
Why?
|
| Tobacco Use Disorder | 1 | 2012 | 114 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 442 | 0.090 |
Why?
|
| Review Literature as Topic | 2 | 2023 | 21 | 0.090 |
Why?
|
| Sentinel Surveillance | 1 | 2010 | 23 | 0.090 |
Why?
|
| Pilot Projects | 4 | 2009 | 865 | 0.090 |
Why?
|
| Simplexvirus | 1 | 2011 | 151 | 0.090 |
Why?
|
| Eating | 1 | 2011 | 166 | 0.090 |
Why?
|
| Methyltransferases | 1 | 2011 | 192 | 0.090 |
Why?
|
| ROC Curve | 2 | 2011 | 781 | 0.090 |
Why?
|
| Area Under Curve | 1 | 2011 | 337 | 0.090 |
Why?
|
| Nicotine | 1 | 2012 | 199 | 0.090 |
Why?
|
| Thromboembolism | 1 | 2011 | 120 | 0.090 |
Why?
|
| Herpes Simplex | 1 | 2011 | 203 | 0.090 |
Why?
|
| Probiotics | 1 | 2011 | 88 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2011 | 292 | 0.090 |
Why?
|
| Absenteeism | 1 | 2009 | 9 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2016 | 1371 | 0.090 |
Why?
|
| Patient Preference | 1 | 2010 | 108 | 0.090 |
Why?
|
| Enema | 2 | 2006 | 39 | 0.090 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2023 | 192 | 0.080 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2009 | 61 | 0.080 |
Why?
|
| Pregnancy | 5 | 2020 | 3010 | 0.080 |
Why?
|
| Family Health | 1 | 2009 | 162 | 0.080 |
Why?
|
| Terrorism | 1 | 2009 | 9 | 0.080 |
Why?
|
| Publication Bias | 1 | 2009 | 13 | 0.080 |
Why?
|
| Hospital Mortality | 2 | 2021 | 386 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2011 | 685 | 0.080 |
Why?
|
| Migraine Disorders | 1 | 2009 | 40 | 0.080 |
Why?
|
| Motivation | 1 | 2012 | 296 | 0.080 |
Why?
|
| Health Education | 1 | 2009 | 105 | 0.080 |
Why?
|
| Adenomatous Polyps | 1 | 2008 | 13 | 0.080 |
Why?
|
| False Positive Reactions | 2 | 2006 | 222 | 0.080 |
Why?
|
| Health Surveys | 1 | 2009 | 240 | 0.080 |
Why?
|
| Postoperative Period | 2 | 2021 | 301 | 0.080 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 166 | 0.080 |
Why?
|
| Capsule Endoscopes | 1 | 2008 | 5 | 0.080 |
Why?
|
| Preoperative Period | 2 | 2019 | 94 | 0.080 |
Why?
|
| Capsules | 1 | 2008 | 37 | 0.080 |
Why?
|
| Homosexuality, Male | 1 | 2011 | 299 | 0.080 |
Why?
|
| Survival Rate | 2 | 2011 | 1889 | 0.080 |
Why?
|
| Gadolinium DTPA | 1 | 2009 | 264 | 0.080 |
Why?
|
| Mice | 7 | 2020 | 11742 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2009 | 779 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 360 | 0.080 |
Why?
|
| Radiography | 1 | 2009 | 809 | 0.070 |
Why?
|
| Angiotensin II | 2 | 2019 | 93 | 0.070 |
Why?
|
| Cattle | 1 | 2008 | 375 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2011 | 575 | 0.070 |
Why?
|
| Mutation | 2 | 2019 | 4132 | 0.070 |
Why?
|
| Delivery of Health Care | 2 | 2024 | 435 | 0.070 |
Why?
|
| Decision Making | 2 | 2022 | 665 | 0.070 |
Why?
|
| Pathology, Clinical | 1 | 2006 | 34 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 233 | 0.070 |
Why?
|
| London | 1 | 2006 | 16 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2007 | 299 | 0.070 |
Why?
|
| Single-Blind Method | 1 | 2006 | 150 | 0.070 |
Why?
|
| Terminology as Topic | 1 | 2008 | 221 | 0.070 |
Why?
|
| Minnesota | 1 | 2006 | 44 | 0.070 |
Why?
|
| Molecular Biology | 1 | 2006 | 89 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 151 | 0.070 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2005 | 13 | 0.060 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2005 | 41 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 433 | 0.060 |
Why?
|
| Short Bowel Syndrome | 1 | 2005 | 38 | 0.060 |
Why?
|
| Abdominal Abscess | 1 | 2004 | 22 | 0.060 |
Why?
|
| Luminescence | 1 | 2024 | 21 | 0.060 |
Why?
|
| Luciferases | 1 | 2024 | 128 | 0.060 |
Why?
|
| Radiographic Image Enhancement | 1 | 2006 | 463 | 0.060 |
Why?
|
| Living Donors | 2 | 2017 | 339 | 0.060 |
Why?
|
| Needs Assessment | 1 | 2005 | 157 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 479 | 0.060 |
Why?
|
| Hong Kong | 1 | 2023 | 45 | 0.060 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2024 | 91 | 0.060 |
Why?
|
| New York City | 2 | 2020 | 61 | 0.060 |
Why?
|
| Biological Factors | 1 | 2023 | 18 | 0.060 |
Why?
|
| Credentialing | 1 | 2023 | 14 | 0.060 |
Why?
|
| Enteral Nutrition | 1 | 2023 | 102 | 0.050 |
Why?
|
| Parkinson Disease | 1 | 2024 | 146 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2019 | 3374 | 0.050 |
Why?
|
| Ethics, Clinical | 1 | 2003 | 48 | 0.050 |
Why?
|
| Medical Futility | 1 | 2003 | 31 | 0.050 |
Why?
|
| Dementia | 1 | 2024 | 193 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 155 | 0.050 |
Why?
|
| Pelvis | 1 | 2023 | 96 | 0.050 |
Why?
|
| Tuberculosis | 1 | 2024 | 121 | 0.050 |
Why?
|
| Procarbazine | 2 | 2012 | 40 | 0.050 |
Why?
|
| Platinum Compounds | 2 | 2012 | 31 | 0.050 |
Why?
|
| Asia | 1 | 2022 | 98 | 0.050 |
Why?
|
| Amino Acids | 1 | 2023 | 245 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2022 | 76 | 0.050 |
Why?
|
| Multiple Sclerosis | 1 | 2024 | 272 | 0.050 |
Why?
|
| Models, Biological | 1 | 2009 | 1764 | 0.050 |
Why?
|
| Cutaneous Fistula | 1 | 2021 | 11 | 0.050 |
Why?
|
| Patient Participation | 1 | 2024 | 224 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2005 | 426 | 0.050 |
Why?
|
| China | 1 | 2022 | 233 | 0.050 |
Why?
|
| Women, Working | 1 | 2021 | 7 | 0.050 |
Why?
|
| Canada | 2 | 2012 | 208 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2008 | 1215 | 0.050 |
Why?
|
| Rheumatic Diseases | 1 | 2022 | 26 | 0.050 |
Why?
|
| Attitude of Health Personnel | 2 | 2024 | 643 | 0.050 |
Why?
|
| Gastrectomy | 1 | 2002 | 69 | 0.050 |
Why?
|
| Education, Medical | 2 | 2021 | 243 | 0.050 |
Why?
|
| Eye Diseases | 1 | 2022 | 58 | 0.050 |
Why?
|
| Asthma | 1 | 2009 | 976 | 0.050 |
Why?
|
| Fissure in Ano | 1 | 2001 | 3 | 0.050 |
Why?
|
| Efficiency | 1 | 2021 | 40 | 0.050 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2021 | 13 | 0.050 |
Why?
|
| New York | 1 | 2021 | 72 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2001 | 118 | 0.050 |
Why?
|
| Employment | 1 | 2021 | 53 | 0.050 |
Why?
|
| Adolescent Development | 1 | 2021 | 21 | 0.050 |
Why?
|
| Nitroglycerin | 1 | 2001 | 23 | 0.050 |
Why?
|
| Mass Vaccination | 1 | 2020 | 9 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2022 | 95 | 0.050 |
Why?
|
| Equipment Design | 2 | 2015 | 415 | 0.050 |
Why?
|
| Malabsorption Syndromes | 1 | 2000 | 21 | 0.050 |
Why?
|
| Minority Groups | 1 | 2022 | 144 | 0.050 |
Why?
|
| Immunomodulation | 1 | 2021 | 58 | 0.050 |
Why?
|
| Mental Health Services | 1 | 2021 | 57 | 0.050 |
Why?
|
| Medical Staff, Hospital | 1 | 2001 | 108 | 0.050 |
Why?
|
| Physicians, Women | 1 | 2021 | 56 | 0.050 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2000 | 39 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2021 | 102 | 0.050 |
Why?
|
| Sigmoidoscopy | 1 | 2020 | 36 | 0.050 |
Why?
|
| Critical Pathways | 1 | 2020 | 37 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 91 | 0.040 |
Why?
|
| Epilepsy | 1 | 2024 | 423 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 60 | 0.040 |
Why?
|
| Teaching | 1 | 2001 | 147 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2001 | 146 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 374 | 0.040 |
Why?
|
| Massachusetts | 1 | 2020 | 32 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2022 | 921 | 0.040 |
Why?
|
| Breast Implantation | 1 | 2020 | 13 | 0.040 |
Why?
|
| Skin Diseases | 1 | 2022 | 173 | 0.040 |
Why?
|
| Diet | 1 | 2023 | 442 | 0.040 |
Why?
|
| World Health Organization | 1 | 2020 | 106 | 0.040 |
Why?
|
| Microvessels | 1 | 2020 | 69 | 0.040 |
Why?
|
| France | 1 | 2019 | 48 | 0.040 |
Why?
|
| Pneumonectomy | 1 | 2002 | 206 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2020 | 111 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2019 | 38 | 0.040 |
Why?
|
| Homeless Youth | 1 | 1999 | 2 | 0.040 |
Why?
|
| Drug Recalls | 1 | 2019 | 13 | 0.040 |
Why?
|
| Seasons | 1 | 2020 | 237 | 0.040 |
Why?
|
| STAT1 Transcription Factor | 1 | 2019 | 53 | 0.040 |
Why?
|
| General Surgery | 1 | 2002 | 235 | 0.040 |
Why?
|
| Primary Health Care | 2 | 2013 | 351 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2019 | 41 | 0.040 |
Why?
|
| Child Development | 1 | 2021 | 167 | 0.040 |
Why?
|
| Image Enhancement | 2 | 2009 | 567 | 0.040 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2002 | 469 | 0.040 |
Why?
|
| Blue Cross Blue Shield Insurance Plans | 1 | 2018 | 3 | 0.040 |
Why?
|
| Nurses | 1 | 2019 | 40 | 0.040 |
Why?
|
| Tissue Expansion Devices | 1 | 2018 | 8 | 0.040 |
Why?
|
| Janus Kinase 2 | 1 | 2019 | 60 | 0.040 |
Why?
|
| Affective Symptoms | 1 | 1999 | 50 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 85 | 0.040 |
Why?
|
| Antipsychotic Agents | 1 | 2020 | 128 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 55 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 343 | 0.040 |
Why?
|
| Risk Management | 1 | 2018 | 43 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 887 | 0.040 |
Why?
|
| Liability, Legal | 1 | 2018 | 32 | 0.040 |
Why?
|
| Prednisolone | 1 | 2018 | 40 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 2552 | 0.040 |
Why?
|
| Placebo Effect | 1 | 2018 | 30 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 240 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 164 | 0.040 |
Why?
|
| Mastectomy | 1 | 2020 | 245 | 0.040 |
Why?
|
| Research | 1 | 2019 | 252 | 0.040 |
Why?
|
| Therapeutic Human Experimentation | 1 | 1997 | 20 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 1088 | 0.040 |
Why?
|
| Central Nervous System Stimulants | 1 | 2020 | 218 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2017 | 41 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2017 | 155 | 0.040 |
Why?
|
| Medicaid | 1 | 2020 | 229 | 0.040 |
Why?
|
| Medical Overuse | 1 | 2017 | 36 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 1999 | 235 | 0.040 |
Why?
|
| Colon, Sigmoid | 1 | 2016 | 6 | 0.040 |
Why?
|
| Fibrosis | 1 | 2018 | 234 | 0.030 |
Why?
|
| Office Visits | 1 | 2017 | 50 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2020 | 475 | 0.030 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2016 | 21 | 0.030 |
Why?
|
| Hydralazine | 1 | 2016 | 19 | 0.030 |
Why?
|
| Fumarates | 1 | 2016 | 19 | 0.030 |
Why?
|
| Losartan | 1 | 2016 | 30 | 0.030 |
Why?
|
| Amides | 1 | 2016 | 53 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2019 | 1130 | 0.030 |
Why?
|
| Bacteroides fragilis | 1 | 2016 | 44 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 412 | 0.030 |
Why?
|
| Occludin | 1 | 2016 | 66 | 0.030 |
Why?
|
| Social Perception | 1 | 2017 | 95 | 0.030 |
Why?
|
| Sex Factors | 2 | 2015 | 1063 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2016 | 86 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2017 | 242 | 0.030 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 46 | 0.030 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2016 | 70 | 0.030 |
Why?
|
| Medicare | 1 | 2020 | 423 | 0.030 |
Why?
|
| Zeolites | 1 | 1995 | 4 | 0.030 |
Why?
|
| Digestive System | 1 | 1995 | 42 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2015 | 70 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 470 | 0.030 |
Why?
|
| Embryonic and Fetal Development | 1 | 1995 | 72 | 0.030 |
Why?
|
| Liver Abscess, Amebic | 1 | 1995 | 1 | 0.030 |
Why?
|
| Entamoeba histolytica | 1 | 1995 | 3 | 0.030 |
Why?
|
| Entamoebiasis | 1 | 1995 | 3 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2017 | 291 | 0.030 |
Why?
|
| Stroke | 1 | 2024 | 982 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2015 | 53 | 0.030 |
Why?
|
| Cadherins | 1 | 2016 | 163 | 0.030 |
Why?
|
| Receptors, Calcitriol | 1 | 2016 | 130 | 0.030 |
Why?
|
| Gadolinium | 1 | 1995 | 103 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 1995 | 88 | 0.030 |
Why?
|
| Sacroiliitis | 1 | 2014 | 3 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2016 | 466 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2015 | 186 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 1996 | 364 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 866 | 0.030 |
Why?
|
| Group Processes | 1 | 2013 | 31 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2013 | 293 | 0.030 |
Why?
|
| Craniocerebral Trauma | 1 | 2013 | 56 | 0.030 |
Why?
|
| Tissue and Organ Procurement | 1 | 1997 | 345 | 0.030 |
Why?
|
| Fetal Blood | 1 | 2012 | 93 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 1574 | 0.030 |
Why?
|
| Child Abuse | 1 | 2013 | 83 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2016 | 688 | 0.030 |
Why?
|
| Phylogeny | 1 | 2017 | 1182 | 0.020 |
Why?
|
| Denmark | 1 | 2011 | 17 | 0.020 |
Why?
|
| Preventive Medicine | 1 | 2010 | 17 | 0.020 |
Why?
|
| Genotype | 1 | 2015 | 1848 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2012 | 2412 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 171 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 313 | 0.020 |
Why?
|
| Age Distribution | 1 | 2011 | 200 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 1997 | 849 | 0.020 |
Why?
|
| Patient Safety | 1 | 2013 | 216 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 282 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 1996 | 754 | 0.020 |
Why?
|
| Selenium | 1 | 1989 | 46 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1717 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 794 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 519 | 0.020 |
Why?
|
| Human Rights Abuses | 1 | 2009 | 2 | 0.020 |
Why?
|
| Israel | 1 | 2009 | 57 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1989 | 80 | 0.020 |
Why?
|
| Arabs | 1 | 2009 | 17 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2012 | 341 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 3211 | 0.020 |
Why?
|
| Claudin-1 | 1 | 2008 | 17 | 0.020 |
Why?
|
| Claudins | 1 | 2008 | 33 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2011 | 228 | 0.020 |
Why?
|
| beta Catenin | 1 | 2008 | 266 | 0.020 |
Why?
|
| Myocardium | 1 | 1989 | 571 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 3000 | 0.020 |
Why?
|
| Phenylhydrazines | 1 | 2005 | 10 | 0.020 |
Why?
|
| Pneumoradiography | 1 | 2005 | 3 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2011 | 2011 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2005 | 81 | 0.020 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2004 | 70 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2009 | 1097 | 0.020 |
Why?
|
| Mice, SCID | 2 | 1995 | 261 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 2005 | 160 | 0.010 |
Why?
|
| Fever | 1 | 2004 | 128 | 0.010 |
Why?
|
| Drainage | 1 | 2004 | 162 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 1998 | 1239 | 0.010 |
Why?
|
| Ointments | 1 | 2001 | 12 | 0.010 |
Why?
|
| Administration, Topical | 1 | 2001 | 96 | 0.010 |
Why?
|
| Xylose | 1 | 2000 | 23 | 0.010 |
Why?
|
| Breath Tests | 1 | 2000 | 57 | 0.010 |
Why?
|
| Workload | 1 | 2001 | 129 | 0.010 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2000 | 62 | 0.010 |
Why?
|
| Medical History Taking | 1 | 2000 | 81 | 0.010 |
Why?
|
| Intelligence | 1 | 1999 | 71 | 0.010 |
Why?
|
| Psychological Tests | 1 | 1999 | 91 | 0.010 |
Why?
|
| Child Behavior Disorders | 1 | 1999 | 76 | 0.010 |
Why?
|
| Educational Status | 1 | 1999 | 194 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2002 | 595 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 1999 | 334 | 0.010 |
Why?
|
| Blood Group Incompatibility | 1 | 1997 | 20 | 0.010 |
Why?
|
| Public Opinion | 1 | 1997 | 42 | 0.010 |
Why?
|
| Peer Review, Research | 1 | 1997 | 36 | 0.010 |
Why?
|
| ABO Blood-Group System | 1 | 1997 | 58 | 0.010 |
Why?
|
| Confidentiality | 1 | 1997 | 77 | 0.010 |
Why?
|
| Hospitals, University | 1 | 1997 | 195 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 1996 | 37 | 0.010 |
Why?
|
| Microcirculation | 1 | 1996 | 104 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 1995 | 39 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 1995 | 26 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1995 | 308 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1995 | 371 | 0.010 |
Why?
|
| Informed Consent | 1 | 1997 | 275 | 0.010 |
Why?
|
| Dogs | 1 | 1995 | 704 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 1995 | 448 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1995 | 738 | 0.010 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1989 | 101 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1995 | 1223 | 0.010 |
Why?
|